The Biosimilars Council Announces Chairman of the Board of Directors, Officers
The Biosimilars Council, a division of the Generic Pharmaceutical Association (GPhA), today announced the election of the first Chairman of its Board of Directors.
WASHINGTON, DC (July 21, 2015) — The Biosimilars Council, a division of the Generic Pharmaceutical Association (GPhA) that works to educate patients and health professionals and to ensure a positive regulatory and policy environment for patient access to biosimilar medicines, today announced the election of the first Chairman of its Board of Directors.
Dr. Bertrand C. Liang, Chief Executive Officer, Pfenex Inc., will be the inaugural Biosimilars Council Chairman. The other leadership roles are Vice Chairman John Pakulski, Executive Director and Head U.S. Biopharmaceutical Affairs, Sandoz, and Treasurer Bruce Lott, Vice President of State Government Relations and Global Biologics Policy, Mylan Inc.
“I am extremely excited to lead the Biosimilars Council efforts to collaborate with patients, health professionals, regulatory agencies and elected officials in order to ensure a positive environment for these promising medicines,” said Liang. “Biosimilars are poised to play a critical role in our nation’s health system — providing patients with safe, effective, more affordable alternatives to costly brand biologic therapies. As the Food and Drug Administration moves forward with its review of biosimilars applications, it is more important now than ever to establish an effective legal and regulatory foundation and ensure that patients and professionals are educated about these medicines. I look forward to working closely with the FDA and other agencies to create a pathway that encourages adoption of these life-impacting drugs.”
The potential savings from biosimilars is great, according to experts cited in The Next Frontier for Access to Medicines: Biosimilars and Interchangeable Biologics, an educational handbook offered by the Biosimilars Council. Estimates from various economic impact studies pin the projected savings from $44 billion on the low end to as high as $250 billion over the first 10 years that only 11 of the most likely biosimilars are available to patients.
“GPhA and its Biosimilars Council remain focused on preserving and promoting access and savings from more affordable medicines,” said Ralph G. Neas, President and CEO, GPhA. “The Biosimilars Council is an unrivaled resource for anyone seeking to navigate this emerging industry, build relationships and be directly involved in formative regulatory, reimbursement, political, and policy conversations.”
The Biosimilars Council Board of Directors includes representatives from the following member companies:
• Amneal BioSciences, LLC
• Dr. Reddy’s
• Momenta Pharmaceuticals, Inc.
• Mylan Inc.
• Pfenex Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals USA
• Therapeutic Proteins International
• Zydus Pharmaceuticals
Visit www.biosimilarscouncil.org for more information.